BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29222279)

  • 21. Follicular Lymphoma: The Management of Elderly Patient.
    Castellino A; Santambrogio E; Nicolosi M; Botto B; Boccomini C; Vitolo U
    Mediterr J Hematol Infect Dis; 2017; 9(1):e2017009. PubMed ID: 28105297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
    Coiffier B; Li W; Henitz ED; Karkera JD; Favis R; Gaffney D; Shapiro A; Theocharous P; Elsayed YA; van de Velde H; Schaffer ME; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Romejko-Jarosinska J; de Vos S; Crump M; Shpilberg O; Zinzani PL; Cakana A; Esseltine DL; Mulligan G; Ricci D
    Clin Cancer Res; 2013 May; 19(9):2551-61. PubMed ID: 23549871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follicular lymphoma: 2014 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2014 Apr; 89(4):429-36. PubMed ID: 24687887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current prognostic and predictive factors in follicular lymphoma.
    Sorigue M; Sancho JM
    Ann Hematol; 2018 Feb; 97(2):209-227. PubMed ID: 29032510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unmet needs in the first-line treatment of follicular lymphoma.
    Casulo C; Nastoupil L; Fowler NH; Friedberg JW; Flowers CR
    Ann Oncol; 2017 Sep; 28(9):2094-2106. PubMed ID: 28430865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.
    Gángó A; Bátai B; Varga M; Kapczár D; Papp G; Marschalkó M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bödör C; Szepesi Á
    Virchows Arch; 2018 Oct; 473(4):453-462. PubMed ID: 29858685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
    Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
    Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
    Reagan PM; Friedberg JW
    Curr Treat Options Oncol; 2015 Jul; 16(7):32. PubMed ID: 26031546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
    Sickinger MT; von Tresckow B; Kobe C; Engert A; Borchmann P; Skoetz N
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010533. PubMed ID: 25572491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.
    Al Khabori M; de Almeida JR; Guyatt GH; Kuruvilla J; Crump M
    J Natl Cancer Inst; 2012 Jan; 104(1):18-28. PubMed ID: 22190633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab maintenance versus retreatment in follicular lymphoma.
    Palla AR; Hamadani M
    Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma--combined performance of multiple markers.
    van den Brand M; Mathijssen JJ; Garcia-Garcia M; Hebeda KM; Groenen PJ; Falini B; Serrano S; van Krieken JH
    Haematologica; 2015 Sep; 100(9):e358-60. PubMed ID: 26069292
    [No Abstract]   [Full Text] [Related]  

  • 39. miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.
    Thompson MA; Edmonds MD; Liang S; McClintock-Treep S; Wang X; Li S; Eischen CM
    Hum Pathol; 2016 Apr; 50():118-26. PubMed ID: 26997445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
    Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
    Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.